Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) (NCT06395103)
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Los Angeles ( Site 1006) — Los Angeles, California
Age range: 6 Months to 25 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (67 Sites)
Showing the first 25 of 67 sites.
- Children's Hospital Los Angeles ( Site 1006) — Los Angeles, California
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) — Aurora, Colorado
- Yale New Haven Hospital ( Site 1012) — New Haven, Connecticut
- Johns Hopkins All Children's Hospital ( Site 1025) — St. Petersburg, Florida
- University of Iowa-Holden Comprehensive Cancer Center ( Site 1017) — Iowa City, Iowa
- Dana-Farber Cancer Institute ( Site 1013) — Boston, Massachusetts
- Corewell Health ( Site 1001) — Grand Rapids, Michigan
- Children's Mercy Hospital ( Site 1024) — Kansas City, Missouri
- Rutgers Cancer Institute of New Jersey ( Site 1008) — New Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center ( Site 1010) — New York, New York
- New York Medical College ( Site 1023) — Valhalla, New York
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003) — Fargo, North Dakota
- Oregon Health and Science University ( Site 1004) — Portland, Oregon
- Children's Hospital of Philadelphia (CHOP) ( Site 1021) — Philadelphia, Pennsylvania
- Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015) — Sioux Falls, South Dakota
- University of Texas MD Anderson Cancer Center ( Site 1007) — Houston, Texas
- Intermountain - Primary Children's Hospital ( Site 1014) — Salt Lake City, Utah
- Sydney Children's Hospital ( Site 1997) — Randwick, New South Wales
- Queensland Children's Hospital-Oncology & Haematology ( Site 1996) — Brisbane, Queensland
- UZ Gent ( Site 1428) — Ghent, Oost-Vlaanderen
- Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268) — Curitiba, Paraná
- Hospital de Clinicas de Porto Alegre ( Site 1265) — Porto Alegre, Rio Grande do Sul
- Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264) — Barretos, São Paulo
- Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267) — São José do Rio Preto, São Paulo
- McGill University Health Centre-Pediatric HematologyOncology ( Site 1223) — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in B-cell Acute Lymphoblastic Leukemia
- A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) — Los Angeles, California
- A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia — Houston, Texas
- Venetoclax Plus Inotuzumab for B-ALL — Boston, Massachusetts
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients — Birmingham, Alabama
- Study Of KITE-753 in R/R B-Cell ALL — Houston, Texas
- A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia — New York, New York
Explore by condition: All B-cell Acute Lymphoblastic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.